Clinical trials: Granulomatosis With Polyangitis
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis
The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when taken with methotrexate in the induction of remission in ANCA-Associated Small Vessel Vasculitis.
- Trial name
- BIANCA-SC (NCT01598857)
- Testing
- Blisibimod
- Sponsor
- Anthera Pharmaceuticals
Vasculitis, Systemic Vasculitis
Journey of Patients With Vasculitis From First Symptom to Diagnosis
This study seeks to understand the journey that patients eventually are diagnosed with vasculitis experience in the period prior to their formal diagnosis by a healthcare provider.
- Conditions
- Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis
- Trial name
- NCT03410290
- Testing
- Online Questionnaire
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- University of Pennsylvania
Vasculitis, Wegener's Granulomatosis
Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
This study will evaluate the safety and effectiveness of a staged approach to therapy for Wegener's granulomatosis and other systemic vasculitides using prednisone plus cyclophosphamide followed by methotrexate.
- Trial name
- NCT00001473
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis
Low-dose Glucocorticoid Vasculitis Induction Study
Previous reports suggested conventional immunosuppressants such as cyclophosphamide could not reduce glucocorticoid dose in remission induction in ANCA-associated vasculitis because of lower remission rate and higher relapse…
- Conditions
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
- Trial name
- LoVAS (NCT02198248)
- Testing
- Rituximab, Glucocorticoids
- Where
- 17 sites in Japan
- Volunteers
- 140 people
- Sponsor
- Chiba University
Rheumatoid Arthritis, Ankylosing Spondylitis
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in which further therapeutic development will be…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Psoriasis
- Trial name
- TRANSREG (NCT01988506)
- Testing
- Interleukin 2
- Where
- 11 sites in France
- Volunteers
- 81 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA)
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
The purpose of this study is to determine the safety and efficacy of a therapeutic regimen consisting of 4 weeks of glucocorticoids given with a combination of the usual induction agents for ANCA-associated vasculitis.
- Trial name
- SAFE-LOW (NCT06983821)
- Testing
- Cyclophosphamide, Standard of Care (SOC), Prednisone
- Where
- 2 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Ottawa Hospital Research Institute
Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
The purpose of the study is to evaluate the efficacy of IFX-1 treatment as replacement for glucocorticoid (GC) therapy in subjects with polyangiitis (GPA) or microscopic polyangiitis (MPA).
- Trial name
- IXchange (NCT03895801)
- Testing
- IFX-1, Glucocorticoid (GC)
- Where
- 76 sites in Belgium, Czechia and 9 more
- Volunteers
- 57 people
- Sponsor
- InflaRx GmbH
Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
- Trial name
- NCT06046222
- Testing
- NS-229
- Where
- 34 sites in United States, Canada and 6 more
- Volunteers
- 45 people
- Sponsor
- NS Pharma, Inc.
Vasculitis, Wegener's Granulomatosis
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
The purpose of this study is to assess the safety, tolerance, and immunologic effects of interleukin-10 (IL-10), in patients with Wegener's granulomatosis.
- Trial name
- NCT00001761
- Testing
- Interleukin-10
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Wegener's Granulomatosis, Microscopic Polyangiitis
Plasma Exchange for Renal Vasculitis
The purpose of this study is to test whether additional therapy with plasma exchange improves the chances of kidney recovery in severe kidney vasculitis.
- Trial name
- MEPEX (NCT01408836)
- Testing
- Plasma exchange, Intravenous methyl prednisolone, Methyl prednisolone
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Eosinophilic Granulomatosis With Polyangiitis
Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)
The purpose of this study is to compare mepolizumab-based regimen to conventional therapeutic strategy for remission induction in patients with Eosinophilic Granulomatosis with Polyangiitis.
- Trial name
- E-merge (NCT05030155)
- Testing
- Mepolizumab, cyclophosphamide/azathioprine
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Granulomatosis With Polyangiitis, Wegener's
TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
This is a single center double-blind placebo-controlled study. Patients with GPA and active ears, nose, and throat (ENT) disease in at least two ENT domains, as defined after endoscopic visualization of the upper airway and…
- Conditions
- Granulomatosis With Polyangiitis, Wegener's, GPA
- Trial name
- NCT07176546
- Testing
- Avacopan
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Robert Spiera, MD
Granulomatosis With Polyangiitis
Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab to induce clinical and serological remission in patients with relapsing PR3-ANCA granulomatosis with polyangiitis.
- Trial name
- OBI-WAN (NCT06940661)
- Testing
- Obinutuzumab
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Granulomatosis With Polyangiitis, Hemophagocytic Syndrome
Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers
The trial was designed as a single-center, randomized, double-blind, single-dose parallel controlled phase I study to evaluate the similarity of pharmacokinetics and safety of Meperizumab injection and NUCALA® in healthy male…
- Trial name
- NCT05353179
- Testing
- Meperizumab injection, NUCALA®
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Vasculitis, Wegener's Granulomatosis
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults.
- Conditions
- Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
- Trial name
- RAVE (NCT00104299)
- Testing
- Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 197 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vasculitis
Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Treatment of patients with PR3-ANCA-associated vasculitis consists of two phases: remission induction with highly effective, but also relatively toxic, drugs and, secondly, after remission is achieved, maintenance therapy with…
- Trial name
- NCT00128895
- Testing
- azathioprine
- Where
- 8 sites in Netherlands
- Volunteers
- 131 people
- Sponsor
- University Medical Center Groningen
Wegener Granulomatosis, Microscopic Polyangiitis
Efficacy Study of Two Treatments in the Remission of Vasculitis
Study of the efficacy of rituximab for maintenance treatment in systemic ANCA-associated vasculitis: prospective, multicenter, controlled, randomized comparative study of rituximab versus azathioprine
- Trial name
- MAINRITSAN (NCT00748644)
- Testing
- Rituximab, Azathioprine
- Where
- France
- Volunteers
- 117 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Wegener's Granulomatosis
Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis
Wegener's granulomatosis is a primary systemic vasculitis characterized by granulomatous and necrotizing inflammation predominantly affecting the respiratory tract and the kidneys.
- Trial name
- NCT00530075
- Testing
- Gusperimus
- Where
- 7 sites in Czechia, Denmark and 4 more
- Volunteers
- 45 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Wegener's Granulomatosis, Churg-Strauss Syndrome
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.
- Conditions
- Wegener's Granulomatosis, Churg-Strauss Syndrome, Microscopic Polyangiitis
- Trial name
- NCT00307593
- Testing
- Infliximab, Rituximab
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Asthma
Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Benralizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5.
- Trial name
- BITE (NCT03010436)
- Testing
- Benralizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Jewish Health